| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.024 | 0.4 |
| mRNA | BRD-K94991378 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.057 | 0.4 |